Atara biotherapeutics announces first clinical data from ongoing tab-cel® european multicenter expanded access program (eap) at the 2022 american society of clinical oncology (asco) annual meeting and update on tab-cel ema regulatory progress

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced ema regulatory progress and tabelecleucel (tab-cel®) clinical outcomes. data is reported from the multicenter expanded access program (eap) study in europe for patients with relapsed or refractory (r/r) epstein-barr virus
ATRA Ratings Summary
ATRA Quant Ranking